Annual Meeting Update: The Latest News in Advanced Breast Cancer
Description: In this video update from the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, leading breast cancer expert, Dr. Hope Rugo, gives her perspective on several areas of research for metastatic breast cancer.
For women with HER2+ breast cancer, ASCO brought results from a Phase III trial that compared trastuzumab emtansine (T-DM1) against the approved combination of lapatinib and capecitabine, the results of which revealed that T-DM1 proved more effective and less toxic as compared to the current standard of therapy.
For women with HER2- breast cancer, Dr. Rugo explains the negative results of a Phase III trial that compared the standard of care paclitaxel against both ixabepilone and nab-paclitaxel. In this case, the experimental arms of the trial appeared to the same or less effective than paclitaxel and both are more toxic.
Dr. Rugo goes on to talk about the upcoming, international, Phase III, Beacon trial examining NKTR-102, a new formulation of irinotecan, a drug that has long been used for the treatment of colon cancer. This trial will focus on patients who have been previously treated with other chemotherapies.
Shared By : patientpower
Posted on : 06/16/12
Added : 5 years ago